June 6, 2023

ACIRNA Therapeutics (formerly Chimeron Bio) recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

Chimeron Bio is now ACIRNA Therapeutics. This announcement was originally issued under the Chimeron Bio name.

Philadelphia, PA: Chimeron Bio (now ACIRNA Therapeutics), a next-generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary Multiplex delivery platform, announced today that the company has been recognized by MilliporeSigma as a finalist in the company’s North American Advance Biotech Grant. As part of the award, Chimeron will receive in-kind products and services from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

“Being recognized as a finalist in MilliporeSigma’s Advance Biotech Grant is an honor,” said Kevin Heyeck, CEO of Chimeron Bio. “It recognizes the unique innovation of our platform, and the support from the MilliporeSigma team will help us expedite our work and further scale solutions for next-generation RNA therapeutics.”

Since 2014, the Life Science business sector’s Advance Biotech Grant program has awarded technologies and consultation to nearly 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis and cardiovascular disorders. MilliporeSigma is set to award its next grant in the APAC region in July, further expanding its commitment to supporting emerging biotech companies worldwide.

About ACIRNA Therapeutics

ACIRNA Therapeutics (formerly Chimeron Bio) is a Philadelphia-based biotechnology company developing next-generation RNA therapeutics engineered to reprogram the immune system. By combining amplified linear and circular RNA architectures with flexible delivery, ACIRNA is building in vivo CAR and immuno-oncology therapies to transform the treatment of cancer and immune-mediated disease. For more information, visit www.acirna.com.